Welcome to our dedicated page for Ocular Therapeut news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeut stock.
Ocular Therapeutix, Inc. reports news around ophthalmic drug development, commercial product activity and corporate governance for a Nasdaq-listed biopharmaceutical company using ELUTYX proprietary bioresorbable hydrogel formulation technology. Recurring updates focus on AXPAXLI, also known as OTX-TKI, an axitinib intravitreal hydrogel candidate for retinal disease, including wet age-related macular degeneration and diabetic retinal disease such as non-proliferative diabetic retinopathy.
Company announcements also cover DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, as well as OTX-TIC, a travoprost intracameral hydrogel program for open-angle glaucoma or ocular hypertension. Other recurring items include financial results, scientific and investor conference participation, clinical-study presentations and inducement equity grants under Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix (NASDAQ: OCUL) announced it will present data from its Phase 1 clinical trial of OTX-TKI, an axitinib intravitreal implant aimed at treating wet AMD, at the Angiogenesis, Exudations, and Degeneration Meeting on February 12-13, 2021. The interim data suggests a favorable safety profile and potential efficacy for OTX-TKI in patients, indicating durability in effects lasting up to six months. Presentation details include time and presenter information, highlighting the significance of the findings for future treatment options in retinal diseases.
Ocular Therapeutix (NASDAQ:OCUL) announced the granting of stock options to a new employee, Dr. Rabia Gurses Ozden, comprising 100,000 shares with time-based vesting and 50,000 shares with performance-based vesting. The options, effective February 1, 2021, have an exercise price of $18.70 per share, matching the closing price on that date. The time-based option vests over four years, while the performance-based option is contingent on achieving specific company milestones. This grant was approved by independent directors as an inducement for Dr. Ozden's employment.
Ocular Therapeutix (NASDAQ: OCUL) announced the presentation of data on OTX-TIC, a travoprost implant for treating primary open-angle glaucoma at the Glaucoma 360 Forum on January 30. Interim Phase 1 trial results showed a mean intraocular pressure reduction of 7-11 mm Hg across cohorts, with durability lasting over six months from a single implant. No serious ocular adverse events were reported, and the hydrogel consistently biodegraded within 5-7 months. The company plans to initiate a Phase 2 trial in mid-2021, emphasizing the potential of OTX-TIC in improving patient compliance with glaucoma treatment.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) has promoted Michael Goldstein, MD, MBA, to President, Ophthalmology, a newly created role where he will oversee clinical and commercial operations. Rabia Gurses Ozden, MD, has been appointed Senior Vice President, Clinical Development, leading the company's growing pipeline. These moves align with the company's strategy to drive growth and innovation in ophthalmic therapies, building upon the success of DEXTENZA, FDA-approved for ocular inflammation treatment. Notably, Ocular is also working on various product candidates in clinical trials.
Ocular Therapeutix, Inc. (Nasdaq: OCUL) announced that underwriters exercised their option to purchase an additional 558,750 shares at $21.50 per share, raising total shares sold to 4,283,750. This resulted in gross proceeds of approximately $92.1 million and net proceeds of around $86.1 million after expenses. The offering, managed by Jefferies LLC and Piper Sandler & Co., was executed under an effective shelf registration statement. Ocular Therapeutix specializes in innovative therapies for eye diseases, with its first product, DEXTENZA®, FDA-approved for treating post-surgery ocular inflammation.
Ocular Therapeutix (NASDAQ:OCUL) has submitted a supplemental New Drug Application (sNDA) to the FDA for DEXTENZA, proposing it for the treatment of ocular itching associated with allergic conjunctivitis. This potential approval could expand DEXTENZA's label for use primarily in ophthalmology offices, appealing to an estimated 10 million patients affected annually. Results from four clinical trials indicate DEXTENZA significantly outperformed placebo in reducing ocular itching. The company expects action on the sNDA by October 2021 under the PDUFA guidelines.
Ocular Therapeutix announced a public offering of 3,725,000 shares at $21.50 each, aiming for gross proceeds of approximately $80.1 million. The offering includes a 30-day option for underwriters to buy an additional 558,750 shares. Jefferies LLC and Piper Sandler & Co. lead the underwriting, with the offering closing on or about December 18, 2020, contingent upon standard conditions. The offering is executed under a shelf registration and aims to fund the development of therapies for eye diseases, enhancing its financial position for future growth.
Ocular Therapeutix, Inc. (Nasdaq: OCUL) has initiated an underwritten public offering of $75 million in common stock, with an option for underwriters to purchase an additional $11.25 million. The offering is subject to market conditions and is made under a shelf registration statement that has been filed with the SEC. Jefferies LLC and Piper Sandler & Co. are the joint book-running managers. Investors are advised to review the prospectus for detailed information before making any investment decisions.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The management team will conduct virtual investor meetings on December 2. A pre-recorded fireside chat presentation is available for streaming on Ocular Therapeutix's investor website, accessible for 90 days. The company focuses on innovative therapies for eye diseases, with FDA-approved DEXTENZA for ocular inflammation and ongoing clinical trials for treatments targeting glaucoma and dry eye disease.
Ocular Therapeutix (NASDAQ:OCUL) announced multiple scientific presentations at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting held from November 13-15, 2020. Highlights include interim Phase 1 data for OTX-TKI, demonstrating safety and biological activity in wet AMD patients. The company also showcased DEXTENZA, emphasizing its efficacy in post-cataract inflammation. Additional studies presented include real-world patient experiences with DEXTENZA, indicating high satisfaction rates. These advancements underline Ocular Therapeutix's commitment to innovative ophthalmic therapies.